Equities researchers at StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a report released on Tuesday. The brokerage set a “sell” rating on the stock.
Navidea Biopharmaceuticals Stock Performance
Shares of NAVB opened at $0.00 on Tuesday. Navidea Biopharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.15. The company has a market cap of $100,084.00, a P/E ratio of -0.02 and a beta of 1.49.
About Navidea Biopharmaceuticals
Want More Great Investing Ideas?
Further Reading
- Five stocks we like better than Navidea Biopharmaceuticals
- Election Stocks: How Elections Affect the Stock Market
- Why the Buy-and-Hold Strategy May Be Best for Most Investors
- 3 Small Caps With Big Return Potential
- Eli Lilly’s Path to the Next Trillion Market Capitalization
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Mobileye Global: CEO Makes $10 Million Bet on Future Strength
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.